Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: Results of a multicenter phase II study on 25 patients

Clinical Cancer Research

Volumn 16, Issue 12, 2010, Pages 3288-3295

  Kérob, Delphine ^a   Porcher, Raphael ^b   Vérola, Olivier ^b   Dalle, Stephane ^c   Maubec, Eve ^d   Aubin, François ^e   D'Incan, Michel ^e   Bodokh, Isaak ^e   Boulinguez, Serge ^e   Madelaine Chambrin, Isabelle ^a   Mathieu Boue, Anne ^f   Servant, Jean Marie ^a   De Kerviler, Eric ^a   Janin, Anne ^b   Calvo, Fabien ^a   Pedeutour, Florence ^g   Lebbe, Celeste ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b INSERM   (France)

^c Dermatology Departments   (France)

^d BICHAT HOSPITAL   (France)

^e Dermatology Departments ^*

^f NOVARTIS PHARMA K K   (Japan)

^g UNIVERSITY HOSPITAL OF NICE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BACKACHE; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; COL1A1 GENE; CONJUNCTIVITIS; DERMATOFIBROSARCOMA PROTUBERANS; DIARRHEA; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GASTROESOPHAGEAL REFLUX; HUMAN; HUMAN TISSUE; HYPERTRANSAMINASEMIA; LIBIDO DISORDER; MACULOPAPULAR RASH; MALE; MULTICENTER STUDY; MUSCLE CRAMP; NAUSEA; NEUTROPENIA; NICK END LABELING; NUCLEAR MAGNETIC RESONANCE IMAGING; PDGFB GENE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; ULTRASOUND; VERTIGO; WEIGHT GAIN;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DERMATOFIBROSARCOMA; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PIPERAZINES; PYRIMIDINES; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 77953700949     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-3401     Document Type: Article

References (31)

1. Bowne WB, Antonescu CR, Leung DH, et al. Dermatofibrosarcoma protuberans: a clinicopathologic analysis of patients treated and followed at a single institution. Cancer 2000;88:2711-20.
2. Fiore M, Miceli R, Mussi C, et al. Dermatofibrosarcoma protuberans treated at a single institution: a surgical disease with a high cure rate. J Clin Oncol 2005;23:7669-75. (Pubitemid 46291832)
3. Sjoblom T, Shimizu A, O'Brien KP, et al. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 2001;61:5778-83. (Pubitemid 32769094)
4. Maki RG, Awan RA, Dixon RH, Jhanwar S, Antonescu CR. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising fromdermatofibrosarcoma protuberans. Int J Cancer 2002;100:623-6. (Pubitemid 34832970)
5. Rubin BP, Schuetze SM, Eary JF, et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 2002;20:3586-91.
6. Bianchini L, Maire G, Guillot B, et al. Complex t(5;8) involving the CSPG2 and PTK2B genes in a case of dermatofibrosarcoma protuberans without the COL1A1-PDGFB fusion. Virchows Arch 2008; 452:689-96.
7. Limon J, Dal Cin P, Sandberg AA. Application of long-term collagenase disaggregation for the cytogenetic analysis of human solid tumors. Cancer Genet Cytogenet 1986;23:305-13. (Pubitemid 17211786)
8. Craver R, Dewenter T, Ebran N, Pedeutour F. COL1A1-PDGFB fusion in a pediatric Bednar tumor with 2 copies of a der(22)t(17;22). Cancer Genet Cytogenet 2006;168:155-7.
9. Maire G, Fraitag S, Galmiche L, et al. A clinical, histologic, and molecular study of 9 cases of congenital dermatofibrosarcoma protuberans. Arch Dermatol 2007;143:203-10. (Pubitemid 46294585)
10. Coindre JM, Hostein I, Maire G, et al. Inflammatory malignant fibrous histiocytomas and dedifferentiated liposarcomas: histological review, genomic profile, and MDM2 and CDK4 status favour a single entity. J Pathol 2004;203:822-30. (Pubitemid 38961569)
11. Zhao WL, Daneshpouy ME, Mounier N, et al. Prognostic significance of bcl-xL gene expression and apoptotic cell counts in follicular lymphoma. Blood 2004;103:695-7. (Pubitemid 38140106)
12. Bauer P, Kohne K. Evaluation of experiments with adaptive interim analyses. Biometrics 1994;50:1029-41.
13. Posch M, Bauer P, Brannath W. Issues in designing flexible trials. Stat Med 2003;22:953-69.
14. Heinrich MC, Joensuu H, Demetri GD, et al. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res 2008;14:2717-25.
15. Mizutani K, Tamada Y, Hara K, et al. Imatinib mesylate inhibits the growth of metastatic lung lesions in a patient with dermatofibrosarcoma protuberans. Br J Dermatol 2004;151:235-7. (Pubitemid 39061309)
16. Labropoulos SV, Fletcher JA, Oliveira AM, Papadopoulos S, Razis ED. Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate. Anticancer Drugs 2005;16: 461-6.
17. Price VE, Fletcher JA, Zielenska M, et al. Imatinib mesylate: an attractive alternative in young children with large, surgically challenging dermatofibrosarcoma protuberans. Pediatr Blood Cancer 2005;44:511-5. (Pubitemid 40614501)
18. Kasper B, Lossignol D, Gil T, Flamen P, De Saint Aubain N, Awada A. Imatinib mesylate in a patient with metastatic disease originating from a dermatofibrosarcoma protuberans of the scalp. Anticancer Drugs 2006;17:1223-5. (Pubitemid 44673404)
19. Savoia P, Ortoncelli M, Quaglino P, Bernengo MG. Imatinib mesylate in the treatment of a large unresectable dermatofibrosarcoma protuberans: a case study. Dermatol Surg 2006;32:1097-102. (Pubitemid 44197467)
20. Mehrany K, Swanson NA, Heinrich MC, et al. Dermatofibrosarcoma protuberans: a partial response to imatinib therapy. Dermatol Surg 2006;32:456-9.
21. Wright TI, Petersen JE. Treatment of recurrent dermatofibrosarcoma protuberans with imatinib mesylate, followed by Mohs micrographic surgery. Dermatol Surg 2007;33:741-4.
22. Lemm D, Mugge LO, Mentzel T, Hoffken K. Current treatment options in dermatofibrosarcoma protuberans. J Cancer Res Clin Oncol 2009;135:653-65.
23. Thomison J, McCarter M, McClain D, Golitz LE, Goldenberg G. Hyalinized collagen in a dermatofibrosarcoma protuberans after treatment with imatinib mesylate. J Cutan Pathol 2008;35:1003-6.
24. Kerob D, Pedeutour F, Leboeuf C, et al. Value of cytogenetic analysis in the treatment of dermatofibrosarcoma protuberans. J Clin Oncol 2008;26:1757-9.
25. Mattox AK, Mehta AI, Grossi PM, Cummings TJ, Adamson DC. Response of malignant scalp dermatofibrosarcoma to presurgical targeted growth factor inhibition. J Neurosurg 2010;112:965-77.
26. Han A, Chen EH, Niedt G, Sherman W, Ratner D. Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans. Arch Dermatol 2009;145:792-6.
27. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.
28. Blay JY, Le Cesne A, Ray-Coquard I, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 2007;25:1107-13. (Pubitemid 46596763)
29. McArthur GA, Demetri GD, van Oosterom A, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol 2005;23:866-73.
30. Torreggiani WC, Al-Ismail K, Munk PL, Nicolaou S, O'Connell JX, Knowling MA. Dermatofibrosarcoma protuberans: MR imaging features. AJR Am J Roentgenol 2002;178:989-93.
31. Sciot R, Debiec-Rychter M. GIST under imatinib therapy. Semin Diagn Pathol 2006;23:84-90.